+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antipsychotic Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5139379
The global market for Antipsychotic Drugs was estimated at US$17.3 Billion in 2023 and is projected to reach US$27.3 Billion by 2030, growing at a CAGR of 6.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Antipsychotic drugs are medications used primarily to manage psychosis, including delusions, hallucinations, and disorders such as schizophrenia and bipolar disorder. These drugs function by altering the effects of neurotransmitters in the brain, particularly dopamine and serotonin, which are implicated in the pathophysiology of psychotic symptoms. There are two main categories of antipsychotic drugs: typical (first-generation) and atypical (second-generation). Typical antipsychotics, such as haloperidol and chlorpromazine, were developed in the 1950s and primarily target dopamine receptors. Atypical antipsychotics, such as risperidone, olanzapine, and aripiprazole, emerged later and act on both dopamine and serotonin receptors, often with fewer side effects related to movement disorders. These medications are crucial in reducing the severity of psychotic episodes, improving the quality of life for individuals with severe mental health conditions.

How Are Antipsychotic Drugs Prescribed and Administered?

The prescription and administration of antipsychotic drugs are tailored to the individual needs of patients, considering factors such as the specific diagnosis, symptom severity, and patient response to treatment. These medications can be administered orally in the form of tablets, capsules, or liquid solutions, or through long-acting injectable formulations. Long-acting injectables (LAIs) have gained popularity due to their ability to maintain therapeutic drug levels over extended periods, enhancing adherence and reducing the frequency of hospitalizations. The treatment regimen often begins with a low dose that is gradually increased to minimize side effects. Regular monitoring by healthcare professionals is essential to manage potential adverse effects and adjust dosages as necessary. Additionally, antipsychotic treatment is frequently combined with psychotherapy and other supportive measures to provide a holistic approach to managing mental health disorders.

What Are the Latest Trends in Antipsychotic Drug Development?

The development of antipsychotic drugs is a rapidly evolving field, driven by ongoing research and innovation aimed at improving efficacy and reducing side effects. One significant trend is the focus on developing drugs with novel mechanisms of action, targeting different neurotransmitter systems or specific receptor subtypes to enhance therapeutic outcomes. Personalized medicine approaches are also gaining traction, with genetic and biomarker studies informing more tailored treatments based on individual patient profiles. Another trend is the integration of digital health technologies, such as mobile apps and wearable devices, to monitor symptoms and medication adherence in real time. The exploration of adjunctive therapies, combining antipsychotic drugs with other pharmacological agents or non-pharmacological interventions like cognitive-behavioral therapy (CBT), is also prominent. These trends reflect a broader commitment to advancing mental health treatment through innovative and patient-centered approaches.

What Is Driving the Growth in the Antipsychotic Drug Market?

The growth in the antipsychotic drug market is driven by several factors, each contributing to the increasing demand and adoption of these medications. One of the primary drivers is the rising prevalence of mental health disorders globally, which underscores the need for effective antipsychotic treatments. Technological advancements in drug formulation and delivery, such as long-acting injectables and digital health tools, enhance patient adherence and therapeutic outcomes. The expanding understanding of the genetic and molecular underpinnings of psychiatric disorders propels the development of more targeted and effective drugs. Furthermore, the destigmatization of mental health issues and increasing awareness campaigns lead to earlier diagnosis and treatment, thereby expanding the patient base. The integration of mental health services into primary care settings and the broader healthcare infrastructure also facilitates access to antipsychotic medications. Additionally, significant investments in research and development by pharmaceutical companies and public health initiatives support the continuous evolution of the antipsychotic drug market. Collectively, these factors create a robust growth trajectory for antipsychotic medications, addressing the complex and diverse needs of individuals with severe mental health conditions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Second Generation Antipsychotic Drugs segment, which is expected to reach US$15.7 Billion by 2030 with a CAGR of a 7.3%. The First Generation Antipsychotic Drugs segment is also set to grow at 6.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $4.5 Billion in 2023, and China, forecasted to grow at an impressive 10.1% CAGR to reach $6.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Antipsychotic Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Antipsychotic Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Antipsychotic Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Johnson & Johnson, Pfizer, Inc., Eli Lilly & Co., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol Meyer Squibb Company
  • AstraZeneca
  • Glaxo SmithKline Plc
  • Allergan

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Antipsychotic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Mental Health Disorders Spurs Market Growth
  • Technological Advancements Propel Growth in Antipsychotic Drug Development
  • Novel Mechanisms of Action Expand Addressable Market Opportunity
  • Personalized Medicine Approaches Strengthen Business Case for Tailored Treatments
  • Adjunctive Therapies Accelerate Demand for Combined Treatment Regimens
  • Long-Acting Injectables Sustain Growth by Enhancing Patient Compliance
  • Increasing Awareness and Destigmatization Throw Spotlight on Antipsychotic Treatments
  • Expansion of Mental Health Services into Primary Care Drives Market Expansion
  • Improved Understanding of Psychiatric Disorders Propels Market Demand
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Schizophrenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Bipolar Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 22: World Antipsychotic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
JAPAN
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
CHINA
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
EUROPE
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Antipsychotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
GERMANY
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Antipsychotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
AUSTRALIA
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol Meyer Squibb Company
  • AstraZeneca
  • Glaxo SmithKline Plc
  • Allergan

Table Information